𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Preventable breast cancer is postmenopausal

✍ Scribed by Kari Hemminki; Asta Försti; Jan Sundquist; Seyed Mohsen Mousavi

Publisher
Springer US
Year
2010
Tongue
English
Weight
385 KB
Volume
125
Category
Article
ISSN
0167-6806

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Arzoxifene for prevention of fractures a
Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women
✍ Steven R Cummings; Michael McClung; Jean-Yves Reginster; David Cox; Bruce Mitlak 📂 Article 📅 2010 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 97 KB

## Abstract Arzoxifene is a selective estrogen receptor modulator (SERM) that has been shown to be more potent in preclinical testing than currently available agents. Its effects on clinical outcomes are not known. In a randomized, blinded trial, women aged 60 to 85 years with osteoporosis, defined

Breast imaging and breast cancer prevent
Breast imaging and breast cancer prevention
✍ Daniel B. Kopans 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 290 KB

Earlier detection of breast cancer through periodic screening is the only currently available intervention likely to reduce breast cancer-related mortality in the near term; prevention would be preferable. The alteration of proliferative changes and the assessment of intermediate endpoints may estab

c-myc amplification is an independent pr
c-myc amplification is an independent prognostic factor in postmenopausal breast cancer
✍ Åke Borg; Bo Baldetorp; Mårten Fernö; Håkan Olsson; Helgi Sigurdsson 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 French ⚖ 681 KB

## Abstract The c‐__myc__ proto‐oncogene was analyzed in 311 cases of primary breast cancer, in 8% of which it was found to be amplified, usually at moderately increased copy number (2‐5 copies). The adjacent pvt gene was co‐amplified with c‐__myc__ in all tumors analyzed. C‐__myc__ amplification w